High affinity human antibodies to human cytomegalovirus (CMV) GB protein
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 27, 2017
Grant Date -
Sep 10, 2015
app pub date -
Apr 27, 2015
filing date -
Jun 16, 2010
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Recombinant monoclonal antibodies to human cytomegalovirus (CMV) gB protein are described. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully